Processa Pharmaceuticals (PCSA) Income from Continuing Operations (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Income from Continuing Operations came in at 3377179.0 in Q1 2026, down 19.15% YoY from 4177065.61 in Q1 2025, and up 8.77% on a QoQ basis from 3701907.0 in Q4 2025.
Processa Pharmaceuticals (PCSA) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Income from Continuing Operations data on file, last reported at 3377179.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 19.15% year-over-year to 3377179.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14526341.0 (down 22.9% YoY) and the FY2025 annual result came in at 2489454.0, up 121.92% from the prior year.
- Income from Continuing Operations improved to 3377179.0 in Q1 2026, from 3701907.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2268456.0 in Q3 2023 to a low of 20044002.0 in Q4 2023.
- A 5-year average of 5044011.06 and a median of 3478090.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 308.7% — and 2024, when it surged 87.54%.
- Tracing PCSA's Income from Continuing Operations over 5 years: stood at 13012320.0 in 2022, then sank by 54.04% to 20044002.0 in 2023, then surged by 87.54% to 2496599.0 in 2024, then tumbled by 48.28% to 3701907.0 in 2025, then grew by 8.77% to 3377179.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3377179.0 (Q1 2026), 3701907.0 (Q4 2025), and 3492552.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | -2.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.38 Mn |
| Dec 31, 2025 | -3.70 Mn |
| Sep 30, 2025 | -3.49 Mn |
| Jun 30, 2025 | -3.95 Mn |
| Mar 31, 2025 | -2.83 Mn |
| Dec 31, 2024 | -2.50 Mn |
| Sep 30, 2024 | -3.48 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -3.03 Mn |
| Dec 31, 2023 | -20.04 Mn |
| Sep 30, 2023 | -2.27 Mn |
| Jun 30, 2023 | -2.61 Mn |
| Mar 31, 2023 | -4.02 Mn |
| Dec 31, 2022 | -13.01 Mn |
| Sep 30, 2022 | -6.02 Mn |
| Jun 30, 2022 | -5.16 Mn |
| Mar 31, 2022 | -3.23 Mn |
| Dec 31, 2021 | -3.18 Mn |
| Sep 30, 2021 | -2.99 Mn |
| Jun 30, 2021 | -3.16 Mn |